AlzheimersDisease
New Alzheimer’s Disease research breakthroughs
New treatment options are unlocking hope for millions of adults and loved ones affected by Alzheimer's
Alzheimer’s Disease was first discovered in the early 1900s by a German doctor, Alois Alzheimer, who had the occasion to examine brain matter of a patient who had passed away after exhibiting memory loss and behavioral challenges. Over the past 100+ years since, Alzheimer’s dementia has come to affect more than 5.5 million Americans, robbing them of precious memories and severely limiting quality of life during what should be the “golden years.”
With such devastating impact on so many as they age, Alzheimer’s Disease has commanded significant attention by way of clinical research. In the 1980s it was discovered that Alzheimer’s is caused by a build-up of plaque called beta-amyloid in the brain. This plaque can disrupt normal cell functioning and lead to the symptoms exhibited by Alzheimer’s dementia – memory loss along with increasing confusion and lack of self-care ability.
In the last year alone, hundreds of clinical trials focused on the disease have been undertaken to better understand the root cause of the condition and to help limit or stall its effects. Until 2021, only two classes of drugs had been approved by the FDA to aid patients suffering with Alzheimer’s: cholinesterase inhibitors such as Aricept that can potentially ease symptoms at any stage, and a receptor antagonist, Memantine, to slow progression in those that are in an early disease state.
The 2020s however have seen more positive activity on the Alzheimer’s front than in any other previous decade. Recently a handful of clinical trials have reported positive results on the Alzheimer’s Disease landscape with two trials leading to fairly rapid FDA approvals. First out of the gate was Aduhelm, a monoclonal antibody approved in 2021 after demonstrating reduced brain plaque in patients with mild disease. The drug is delivered via a monthly infusion to help slow cognitive decline in people at the early stages of decline.
Shortly after Aduhelm was announced, the FDA issued another accelerated approval for a different monoclonal antibody demonstrated to also clear the presence of amyloid plaque in the brain. Leqembi, like Aduhelm, is given to patients with mild cognitive impairment via an intravenous infusion. In a research study with 1,800 participants diagnosed with early-stage disease, the therapy helped reduce decline in thinking by 27 percent over an 18-month period.
In 2023, a report stemming from a clinical trial of yet another monoclonal antibody, donanemab, was released showing even more promising results. In a study of 1,700 participants, more than one-third experienced slower mental decline when compared with participants on placebo. In addition, 47 percent of participants in the trial assigned to the therapy experienced stable disease, meaning disease that did not worsen, over the course of the trial. Plans are underway for an FDA review of the IV therapy drug later in 2023.
With any treatment, there are risks and benefits to be weighed based on the whole-health picture of a patient. But for Alzheimer’s patients and their loved ones, recent progress such as that reported with new monoclonal antibody therapies shown to help remove amyloid plaque are providing much needed glimmers of hope.
Keep up to date on the latest research
Interested in learning more about Alzheimer’s disease? Register on ClinicalResearch.com to receive news about Alzheimer's disease and related IQVIA clinical trials. Check ClinicalResearch.com often for updates and news on a variety of disease areas and to find out more about some of the latest clinical research trials.
With such devastating impact on so many as they age, Alzheimer’s Disease has commanded significant attention by way of clinical research. In the 1980s it was discovered that Alzheimer’s is caused by a build-up of plaque called beta-amyloid in the brain. This plaque can disrupt normal cell functioning and lead to the symptoms exhibited by Alzheimer’s dementia – memory loss along with increasing confusion and lack of self-care ability.
In the last year alone, hundreds of clinical trials focused on the disease have been undertaken to better understand the root cause of the condition and to help limit or stall its effects. Until 2021, only two classes of drugs had been approved by the FDA to aid patients suffering with Alzheimer’s: cholinesterase inhibitors such as Aricept that can potentially ease symptoms at any stage, and a receptor antagonist, Memantine, to slow progression in those that are in an early disease state.
The 2020s however have seen more positive activity on the Alzheimer’s front than in any other previous decade. Recently a handful of clinical trials have reported positive results on the Alzheimer’s Disease landscape with two trials leading to fairly rapid FDA approvals. First out of the gate was Aduhelm, a monoclonal antibody approved in 2021 after demonstrating reduced brain plaque in patients with mild disease. The drug is delivered via a monthly infusion to help slow cognitive decline in people at the early stages of decline.
Shortly after Aduhelm was announced, the FDA issued another accelerated approval for a different monoclonal antibody demonstrated to also clear the presence of amyloid plaque in the brain. Leqembi, like Aduhelm, is given to patients with mild cognitive impairment via an intravenous infusion. In a research study with 1,800 participants diagnosed with early-stage disease, the therapy helped reduce decline in thinking by 27 percent over an 18-month period.
In 2023, a report stemming from a clinical trial of yet another monoclonal antibody, donanemab, was released showing even more promising results. In a study of 1,700 participants, more than one-third experienced slower mental decline when compared with participants on placebo. In addition, 47 percent of participants in the trial assigned to the therapy experienced stable disease, meaning disease that did not worsen, over the course of the trial. Plans are underway for an FDA review of the IV therapy drug later in 2023.
With any treatment, there are risks and benefits to be weighed based on the whole-health picture of a patient. But for Alzheimer’s patients and their loved ones, recent progress such as that reported with new monoclonal antibody therapies shown to help remove amyloid plaque are providing much needed glimmers of hope.
Keep up to date on the latest research
Interested in learning more about Alzheimer’s disease? Register on ClinicalResearch.com to receive news about Alzheimer's disease and related IQVIA clinical trials. Check ClinicalResearch.com often for updates and news on a variety of disease areas and to find out more about some of the latest clinical research trials.
Published Date March 13, 2024
Latest News
Multiple Myeloma
Life with a rare disease
Experiencing serious health challenges is difficult enough - having a relatively unknown condition adds additional complexity
2024-04-22T22:02:00Z
Nonalcoholic Steatohepatitis (NASH)
Speaking with your PCP about MASH
Engaging your primary doctor in a conversation about risk for MASH liver disease doesn't have to be scary
2024-04-09T12:15:00Z
Alzheimer's Disease
New Alzheimer’s Disease research breakthroughs
The 2020s have been the most impactful decade so far for the debilitating form of dementia
2024-03-13T18:30:00Z
Breast Cancer
Talking to family about cancer genes
Though this conversation may be difficult, it might be vitally important for your loved ones
2024-02-05T18:30:00Z
Lupus
Lupus (Systemic Lupus Erythematosus) and Diet
Can what you eat make a difference?
2024-04-15T18:30:00Z
Nonalcoholic Steatohepatitis (NASH)
Learning you need a liver biopsy: staying calm
Approaches to stay in control before, during and after a biopsy
2023-12-27T18:30:00Z
Diabetes
The recent rise of walking as exercise
Grab your sneakers, grab a friend, or grab your dog and get moving!
2023-12-05T18:30:00Z
Renal Cell Carcinoma
Coping with the holidays during cancer treatment
Getting ready to face a new year while facing cancer is no easy task
2023-11-23T18:30:00Z
Multiple Sclerosis (MS)
Possible link between multiple sclerosis and viral infection?
Researchers are looking to learn more about if and how a virus can trigger multiple sclerosis
2023-10-25T18:30:00Z
Nonalcoholic Steatohepatitis (NASH)
Making lifestyle changes: ten ideas to get started
Losing excess weight together with an active lifestyle helps with the management of MASH, but where to begin?
2023-09-05T18:30:00Z
Lung Cancer
Talking to loved ones about your clinical trial
How to talk to family and friends when you are thinking of changing cancer treatment plans for a research option
2023-08-14T18:30:00Z
Lung Cancer
Learning you have lung cancer as a non-smoker
Lung cancer can be a shocking diagnosis when you've never smoked - how can it be?
2023-08-15T18:30:00Z
Prostate Cancer
Does a high PSA score always mean cancer?
Learn more about this common test for older men and how it relates to cancer risk
2023-07-10T18:30:00Z
Breast Cancer
Understanding the differences between mastectomy and lumpectomy
Two different surgical options both seeking the same outcome
2024-05-01T18:30:00Z
Lupus
New treatments are on the horizon for lupus patients
From biologics to CAR-T, developments in clinical research for SLE have opened new treatment doors for patients.
2023-05-22T16:15:00Z
Multiple Myeloma
Understanding eligibility criteria for clinical research studies
Clinical trials utilize sets of criteria to determine if a person is a good fit - but what are these and what do they mean?
2023-04-05T18:30:00Z
Renal Cell Carcinoma
Learning you need a biopsy: staying calm
Approaches to stay in control before, during and after a diagnostic biopsy
2023-03-14T18:30:00Z
Nonalcoholic Steatohepatitis (NASH)
Making lifestyle changes: ten ideas to get started
Pharmaceutical companies are rushing to fill the NASH treatment gap
2023-03-14T18:30:00Z
Breast Cancer
Understanding the differences between mastectomy and lumpectomy_For Testing
Two different surgical options both seeking the same outcome_For Testing
2024-05-01T18:30:00Z